AAD: American Association of Dermatology – Page 3 – MDConnect

AAD 2024

Integrated Cardiovascular Safety Analysis of Ritlecitinib in Patients with Alopecia Areata (AA) in the Phase 2 and Phase 3 ALLEGRO Clinical Trials, and Contextualization with a US Cohort of Patients with AA

This session was presented on March 9 2024 at the American Academy of Dermatology (AAD) Annual Meeting 2024 held in San Diego between March 8-12,

April 1, 2024

AAD 2024

Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 2.3 years and up to 4 Years of Exposure

This session was presented on March 9 2024 at the American Academy of Dermatology (AAD) Annual Meeting 2024 held in San Diego between March 8-12,

March 30, 2024

AAD 2024

Immunohistochemical Differentiation of Keratins and Involucrin between Palmar Psoriasis, Chronic Hand Eczema, and Hyperkeratotic Hand Dermatitis

This session was presented on March 9 2024 at the American Academy of Dermatology (AAD) Annual Meeting 2024 held in San Diego between March 8-12,

March 29, 2024

AAD 2024

Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2- year Results from the CorEvitas Psoriasis Registry

This session was presented on March 8 2024 at the American Academy of Dermatology(AAD) Annual Meeting 2024 held in San Diego between March 8-12 2024

March 28, 2024

AAD 2024

Efficacy of Risankizumab Versus Apremilast Among Patients with Scalp or Nail Psoriasis from the Phase 4 IMMpulse Study

This session was presented on March 8 2024 at the American Academy of Dermatology(AAD) Annual Meeting 2024 held in San Diego between March 8-12 2024

March 27, 2024

AAD 2024

The Emerging Global Threat of Multidrug- Resistant Candida Auris – A Case of Deep Fungal Cutaneous Infection

This session was presented on March 8 2024 at the American Academy of Dermatology(AAD) Annual Meeting 2024 held in San Diego between March 8-12 2024

March 26, 2024

AAD 2024

Efficacy of 1% Clotrimazole Powder Monotherapy for Treatment of Tinea Cruris: A Comparative Randomized Study

This session was presented on March 8 2024 at the American Academy of Dermatology(AAD) Annual Meeting 2024 held in San Diego between March 8-12 2024

March 21, 2024

AAD 2024

A Longitudinal Cohort Study of Squalene Epoxidase Gene Mutations in U.S. Onychomycosis Patients from 2022 to 2023 – Implications for Terbinafine Resistance

This session was presented on March 8 2024 at the American Academy of Dermatology(AAD) Annual Meeting 2024 held in San Diego between March 8-12 2024

March 20, 2024

AAD 2024

Global Prevalence of Autoimmune Diseases in Patients with Vitiligo: A Systematic Review

This session was presented on March 8 2024 at the American Academy of Dermatology(AAD) Annual Meeting 2024 held in San Diego between March 8-12 2024

March 19, 2024

AAD 2024

Vitiligo, Nutrition and the Gut Microbiome: A Narrative Review

This session was presented on March 8 2024 at the American Academy of Dermatology(AAD) Annual Meeting 2024 held in San Diego between March 8-12 2024

March 18, 2024